ALBIO Biosynex SA

0.8731USD0.7960 EUR · EPA-1.73%Mkt Cap: 16.09M USDP/E: —

Biosynex SA designs, manufactures, and distributes rapid diagnostic tests to patients and healthcare professionals in France and internationally. The company develops and markets IVDs in the form of RDTs and TRODs, immun…

Key Statistics

Company
Market Cap16.09M USD
Enterprise Value75.24M USD
Revenue (TTM)104.41M USD
Gross Profit57.42M USD
Net Income (TTM)-63.86M USD
Revenue/Share5.66 USD
Last Price0.8731 USD
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees397
CountryFR
SectorHealthcare
IndustryMedical Devices
ISINFR0011005933
Valuation
P/E (Trailing)—
P/E (Forward)1.73
PEG—
EV/EBITDA-5.03
EV/Revenue0.72
P/S0.15
P/B0.40
EPS (TTM)-4.42 USD
EPS (Forward)0.50 USD
52W Range
0.499031% of range1.722
52W High1.722 USD
52W Low0.4990 USD
Profitability
Gross Margin55.00%
Oper. Margin17.37%
EBITDA Margin-14.33%
Profit Margin-61.16%
ROE-166.59%
ROA-42.74%
ROIC-70.53%
ROCE-58.84%
Growth
Revenue Growth-5.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF-6.46M USD
CapEx (TTM)2.94M USD
FCF Margin14.89%
FCF Yield96.60%
Net Debt58.34M USD
Net Debt/EBITDA-3.90
Net Debt/FCF3.75
Balance Sheet
Debt/Equity1.76
Current Ratio0.64
Quick Ratio0.33
Book Value/Sh2.19 USD
Cash/Share0.50 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio131.58%
Ex-Div DateMay 16, 2022
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.18.43M
Float7.63M
Insiders57.60%
Institutions0.00%
Technical
SMA 500.9390 (-7.0%)
SMA 2000.9887 (-11.7%)
Beta0.78
S&P 52W Chg12.00%
Avg Vol (30d)18.20K
Avg Vol (10d)4.46K
Technical Indicators
RSI (14)39.3
MACD-0.0114
MACD Signal-0.0105
MACD Hist.-0.0009
BB Upper0.9413 USD
BB Middle0.9058 USD
BB Lower0.8704 USD
BB Width7.83%
ATR (14)0.0354 USD
Vol Ratio (20d)1.37x

About Biosynex (EPA: ALBIO)

›

Biosynex (EPA: ALBIO) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 397 employees.

The shares were at 0.7960 EUR on 19 November 2026, up 53.1% over 52 weeks. Its 52-week range is 0.4550 EUR to 1.570 EUR: the price is 49.3% below the high and 74.9% above the low.

Its market capitalisation is 14.67M EUR.

Biosynex reports return on equity of -166.6%, an operating margin of 17.4% and revenue down 5.8% year over year.

Its debt exceeds its cash by 53.19M EUR, a debt-to-equity ratio of 1.76. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.